Updated: Dec 16, 2021
U.K.’s Synaptixbio Ltd. has launched, aiming to tackle a rare and often fatal disease of the central nervous system (CNS), TUBB4a leukodystrophy.
To continue reading please go to the article on BioWorld
Dr Dan Williams, CEO and Co-Founder of new biotech business SynaptixBio, discusses how the search is on to find the first treatment for one of the world’s rarest diseases, TUBB4A-associated leukodystr
SynaptixBio, an Oxford, UK-based research company, has been launched by a worldwide team of medical and pharmaceutical scientists to develop the world’s first disease modifying treatment for leukodyst
